Harpoon Therapeutics to Host Clinical Pipeline Programs Update Call and Webcast on December 8, 2020

Posted: December 7, 2020 at 4:58 pm

SOUTH SAN FRANCISCO, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that it will host a conference call and webcast to review the status and provide a clinical update for its three most advanced TriTAC® programs. The discussion will be focused on HPN424 for the treatment of metastatic castration resistant prostate cancer, HPN536 initially in development for ovarian and pancreatic cancer and mesothelioma, and HPN217 for relapsed/refractory multiple myeloma.

Continue reading here:
Harpoon Therapeutics to Host Clinical Pipeline Programs Update Call and Webcast on December 8, 2020

Related Posts